Join us on June 24 at 4:00 pm US ET for this special webinar on the findings from Fulcrum Therapeutics’ ReDUX4 clinical trial. The Fulcrum team will be sharing the data from its Phase 2b clinical trial of Losmapimod, a treatment for FSH muscular dystrophy that is intended to stop the expression of the DUX4… Read More »
FSHD University Webinar – Fulcrum Clinical Trial Results
The Job Talk
Lynn Stevens from Goodwill Industries of Northern Louisiana gave a superb webinar sharing much valuable information for anyone with a disability about resources to help people find and keep gainful employment. For anyone living with FSH muscular dystrophy, having this information handy can bring much peace of mind in planning the future. Noting that the… Read More »
Tell your doctor about the FSHD Masterclass
The FSHD Society is offering its first-ever CME-accredited masterclass on facioscapulohumeral muscular dystrophy (FSHD). This course, which will be held virtually on August 12, is of interest to any physician and allied health professional who sees adult and pediatric neuromuscular patients. They will be able to earn up to 4.25 continuing medical education (CME) credits—a… Read More »
Dave Younger’s exercise arsenal
by David Younger, Austin, Texas Over the past ten to fifteen years, I have developed an arsenal of products that I use to stay as healthy and active as possible. When COVID started, I bought two inexpensive lung exercisers on Amazon. I use the FIGERM breathing trainer twice a day, in the morning and in… Read More »
Dynamics of DUX4 downstream networks
by Lawrence J. Hayward, MD PhD, University of Massachusetts Medical School To develop robust therapies for FSHD, we need a better understanding of the sequence of events occurring at the single-cell level upon expression of DUX4, the causative gene. A recent paper by Chau et al. from the Yokomori lab at the University of California… Read More »